Long Ideas - Two pertinent announcements from Lexicon Pharmaceuticals (NASDAQ:LXRX) are giving shares a 7% lift on Friday morning. The company reported top-line data from the latest Phase … Continue Reading
Read nowLong Ideas - With Biogen-Idec’s (NASDAQ:BIIB) new multiple sclerosis (MS) treatment, BG-12, approaching a decision by the FDA (PDUFA date December 28th), enthusiasm in the medical community is … Continue Reading
Read nowShort Ideas - Optimer Pharmaceuticals (NASDAQ:OPTR) is hosting its Analyst Day in NYC this morning and is detailing its new strategy, which includes lowering the price for lead … Continue Reading
Read nowLong Ideas - By now, the bear story on Questcor Pharmaceuticals (NASDAQ:QCOR) is well understood, with health insurer Aetna (NYSE:AET) indicating that it will make it next-to-impossible to … Continue Reading
Read nowQuick Picks - Early Monday, Cell Therapeutics (NASDAQ:CTIC) announced that its JAK2 inhibitor pacritinib demonstrated good tolerability and evidence of cancer-fighting behavior in a 34 patient Phase I … Continue Reading
Read nowLong Ideas - Amarin Corp. (NASDAQ:AMRN) is under pressure for a second day on investor concerns related to the FDA pushing back a decision on NCE status for … Continue Reading
Read nowQuick Picks - On Wednesday morning, Opexa Therapeutics (NASDAQ:OPXA) announced the initiation of a Phase IIb trial, called Alibi-T, for Tcelna, the company’s T-cell therapy for multiple sclerosis. … Continue Reading
Read now